CD163 and glioblastoma: In an attempt to characterize the phenotype of systemic M2 monocytes of GBM patients, we performed a quadruple staining (CD14, CD163, PD-L1, FKBP51s) of PBMCs from 14 GBM patients and 14 control donors.